The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Esperion Therapeutics has a potential blockbuster drug that is gaining traction among the medical community. The company's main drugs, NEXLIZET and NEXLETOL, have been approved by the FDA and offer ...

Esperion is a deeply undervalued company selling a new treatment in the huge and lucrative market for lowering LDL cholesterol. ESPR is highly-leveraged to Covid-reopening, but unlike many industries, ...

Shares of Esperion Therapeutics ESPR have surged nearly 44% over the past month. The upside was largely driven by the announcement of a definitive agreement with Archimed, a leading investment firm ...

Esperion Therapeutics (ESPR) has been beaten down lately with too much selling pressure. While the stock has lost 51% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Esperion Therapeutics (ESPR) shares ended the last trading session 6.5% higher at $8.17. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Esperion Therapeutics ESPR announced that it has nominated ESP-2001, a highly specific allosteric ATP citrate lyase (“ACLY”) inhibitor, as its new preclinical development candidate for the treatment ...